Pulmonary Arterial Hypertension (PAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034
Pulmonary Arterial Hypertension (PAH) Emerging Therapy Thelansis’s “Pulmonary Arterial Hypertension (PAH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Pulmonary Arterial Hypertension (PAH) Overview Pulmonary arterial hypertension (PAH) is a progressive and chronic condition marked by antiproliferative changes in the pulmonary arterioles, resulting in endothelial and smooth muscle proliferation and dysfunction, inflammation, and the formation of blood clots. PAH is primarily caused by remodeling of pulmonary arteries, narrowing, and obstructing the smallest arteries. This increased resistance in the pulmonary circulation results in elevated pressure within the right ventricle. Specific gene mutations, inclu...